Abstract
Alzheimers disease (AD) is characterized by two major features: (1) degeneration of basal forebrain cholinergic neurons and ensuing deficient cholinergic functions in cortex and hippocampus; (2) extracellular protein aggregates containing β-amyloid peptides (Aβ) in these cholinergic target areas. So far, the most effective therapy for AD is to enhance cholinergic transmission. Neuromodulatory functions of the cholinergic system are mainly mediated by muscarinic receptors (mAChRs). It has long been recognized that mAChRs are crucial for the control of high-level cognitive processes. Drugs that activate mAChRs are helpful in ameliorating cognitive deficits of AD. On the other hand, mounting evidence have established detrimental effects of Aβ to cognitive functions. Despite intensive research on AD, it remains unclear how these two prominent features of the disease may be linked to cause cognitive impairments. In this review, we will summarize a series of recent findings on the interactions between cholinergic functions and β-amyloid in normal animals and AD models, and discuss their potential implications in the pathophysiology and treatment of Alzheimers disease.
Keywords: alzheimers disease, cholinergic, muscarinic receptors, amyloid peptides, insulin, gabaergic transmission, prefrontal cortex, protein kinase c
Current Alzheimer Research
Title: Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid
Volume: 1 Issue: 4
Author(s): Zhen Yan and Jian Feng
Affiliation:
Keywords: alzheimers disease, cholinergic, muscarinic receptors, amyloid peptides, insulin, gabaergic transmission, prefrontal cortex, protein kinase c
Abstract: Alzheimers disease (AD) is characterized by two major features: (1) degeneration of basal forebrain cholinergic neurons and ensuing deficient cholinergic functions in cortex and hippocampus; (2) extracellular protein aggregates containing β-amyloid peptides (Aβ) in these cholinergic target areas. So far, the most effective therapy for AD is to enhance cholinergic transmission. Neuromodulatory functions of the cholinergic system are mainly mediated by muscarinic receptors (mAChRs). It has long been recognized that mAChRs are crucial for the control of high-level cognitive processes. Drugs that activate mAChRs are helpful in ameliorating cognitive deficits of AD. On the other hand, mounting evidence have established detrimental effects of Aβ to cognitive functions. Despite intensive research on AD, it remains unclear how these two prominent features of the disease may be linked to cause cognitive impairments. In this review, we will summarize a series of recent findings on the interactions between cholinergic functions and β-amyloid in normal animals and AD models, and discuss their potential implications in the pathophysiology and treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Yan Zhen and Feng Jian, Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid, Current Alzheimer Research 2004; 1 (4) . https://dx.doi.org/10.2174/1567205043331992
DOI https://dx.doi.org/10.2174/1567205043331992 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews Neuroprotection for Amyotrophic Lateral Sclerosis: Role of Stem Cells, Growth Factors, and Gene Therapy
Central Nervous System Agents in Medicinal Chemistry Scorpion Toxin-potassium Channel Interaction Law and its Applications
Venoms and Toxins Neurotoxicity of β-Amyloid Protein: Oligomerization, Channel Formation and Calcium Dyshomeostasis
Current Pharmaceutical Design The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Bitter Gourd (Momordica charantia) is a Cornucopia of Health: A Review of its Credited Antidiabetic, Anti-HIV, and Antitumor Properties
Current Molecular Medicine Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Multivariate Statistical Tools for the Evaluation of Proteomic 2D-maps:Recent Achievements and Applications
Current Proteomics Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets
Current Pharmaceutical Design Gut Emotions - Mechanisms of Action of Probiotics as Novel Therapeutic Targets for Depression and Anxiety Disorders
CNS & Neurological Disorders - Drug Targets Improving the Stability of Aptamers by Chemical Modification
Current Medicinal Chemistry The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Cilostazol: Therapeutic Potential Against Focal Cerebral Ischemic Damage
Current Pharmaceutical Design Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design